QTTB 241220 12.50C (QTTB241220C12500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

QTTB241220C12500

Watchlist

0.04
-0.01-20.00%

15min DelayClose Dec 13 10:38 ET

0.04High0.04Low

Intraday

5D
Daily

News

Express News | Q32 Bio Inc Shares Hit Record Low After Guggenheim Downgrades Stock, Last Down 21.2%
ReutersDec 12 12:00 ET
Q32 Bio Is Maintained at Outperform by BMO Capital
Dow JonesDec 12 11:27 ET · Ratings
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday
Zacks Dec 12 10:35 ET
BMO Capital Maintains Q32 Bio(QTTB.US) With Buy Rating, Cuts Target Price to $22
Moomoo NewsDec 12 10:32 ET · Ratings
Guggenheim Downgrades Q32 Bio to Neutral
BenzingaDec 12 10:14 ET
Q32 Bio Analyst Ratings
BenzingaDec 12 10:07 ET · Ratings

Comments

Dec 12 09:36

$Q32 Bio (QTTB.US)$$50 to 0.50

2017x

Dec 12 09:26

$Q32 Bio (QTTB.US)$ How much further can it drop?

👁

🟢 Watchlist WEDNESDAY December 11. NFA

NOTE: I don’t have time to include those in my watchlist which didnt run. Just go back to it because those stocks will go usually after days or a week.
Sorry I am sleepy cant finish the list.
$Rigetti Computing (RGTI.US)$ PR today 12/10: Quantum Machines And Rigetti Computing Announces The Application Of AI To Automate The Calibration Of A Quantum Computer. Up after hours. SI 13.89%, 0 shares LTB✅
$SEALSQ Corp (LAES.US)$ PR 12/10: Partnership with IC’ALPS to ...

Jaguar8

Dec 10 15:10

NEWS

$Q32 Bio (QTTB.US)$
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program
Tuesday, 10th December at 4:05 pm
-- SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 response --
-- SIGNAL-AD Phase 2a clinical trial in atopic dermatitis demonstrated promising findings in Part A but did not meet ...